Urethral stents in benign prostate hyperplasia

Donnell, Robert F.

doi:10.1007/s11934-003-0085-0

Cited by 5 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Placement of MSs in the urethra was promising but significant problems such as the frequent presence of stent encrustation, infection, migration and lower urinary tract symptoms limited the use of urethral MSs. [1921] Infact, long-term experience showed high failure rates and significant difficulty in the management of failed urethral MSs since the removal of the stent may require complex reconstructive surgery. [222324]…”

Section: Urological Metal Stentsmentioning

confidence: 99%

Drug-eluting metallic stents in urology

et al. 2014

View full text Add to dashboard Cite

Drugeluting metal stents (DESs) have been extensively used in coronary and vascular disease. This type of stents has been proven to provide significantly lower restenosis rates due to the reduction of neo-intimal hyperplasia in comparison to the traditionally used bare metal stents (BMSs). The latter stents have been evaluated for more than a decade in urological practice in an attempt to provide permanent relief of urethral or ureteral obstruction. Although the initial results were promising, long-term experience revealed significant complications, which are mainly attributed to stent-related hyperplastic reaction compromising stent patency. The favorable experience of vascular DESs led to the application of DESs in both the urethra and ureter of animal models. These experimental results demonstrated a reduction of hyperplastic reaction of DESs in comparison to BMSs. Nevertheless, clinical data are currently not available. Considering the fact that DESs are under continuous development, the use of DESs in urology holds promise for the future and seems to be an intriguing field.

show abstract

Section: Urological Metal Stentsmentioning

confidence: 99%

Drug-eluting metallic stents in urology

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Stents theoretically establish a patent lumen that allows low pressure urinary voiding [14]. The criteria for an optimal stent were identified at the Third International Consultation on Benign Prostatic Hyperplasia in 1995 (table 1) [15].…”

Section: Introductionmentioning

confidence: 99%

First Experiences with the Spanner™ Temporary Prostatic Stent for Prostatic Urethral Obstruction

Goh

Kastner²,

Khan³

et al. 2013

Urol Int

View full text Add to dashboard Cite

Objectives: To assess the ease of insertion and removal of a temporary prostatic stent (the Spanner™) following the use of a prostatic urethral measuring device (the Surveyor™). Patients and Methods: Patients with bladder outflow obstruction or urinary retention awaiting definitive surgery were fully consented. Data were collected pre- and post-insertion and patients followed-up until definitively treated. Results: 16 patients had the Spanner inserted following use of the Surveyor. All insertions were uncomplicated. 14 patients were able to void satisfactorily immediately post-insertion with a mean Q_max of 15.0 ml/s and post-void residual of 51.3 ml. No symptomatic infection was reported. The stents stayed in situ for a median of 10 days. 12 stents were removed prematurely due to severe symptoms or retention. A total of 12 stents had to be removed endoscopically. Conclusions: The Spanner is easy to insert. Stent removal via the retrieval suture has been difficult necessitating the use of endoscopy in the majority of cases. Possible causes of stent failure include underestimation of the prostatic urethral length by the Surveyor leading to obstruction by apical prostatic tissue, excessive suture length between the stent and distal anchor permitting proximal migration or inadequate suture length leading to urinary incontinence. Further design modifications are suggested.

show abstract

Urological Symptoms and Side Effects of Treatment

Abdi

2010

The MASCC Textbook of Cancer Supportive Care and Survivorship

View full text Add to dashboard Cite

Urethral stents in benign prostate hyperplasia

Cited by 5 publications

References 36 publications

Drug-eluting metallic stents in urology

Drug-eluting metallic stents in urology

First Experiences with the Spanner™ Temporary Prostatic Stent for Prostatic Urethral Obstruction

Urological Symptoms and Side Effects of Treatment

Contact Info

Product

Resources

About